# Realcan Pharmaceutical Group

Realcan Pharmaceutical Group is a Corporate Investor based in Yantai, China.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Yantai, China
- **Region:** Asia
- **Address:** No. 326, Airport Road, Zhifu District, Yantai, Shandong, China
- **Founded:** 2004
- **Assets under management:** Undisclosed
- **Website:** realcan.cn

## Regulatory record

- **Reports private funds:** No

## About

Zhang Renhua and Han Xuxiao founded Realcan in 2004, initially focused on pharmaceutical distribution in Shandong province. The firm expanded methodically into a national logistics network spanning all 31 mainland provinces, with direct institutional relationships covering upwards of 60,000 hospitals and clinics. Realcan went public on the Shenzhen Stock Exchange, embedding a permanent capital structure that funds both organic logistics buildout and opportunistic corporate investment. Beyond distribution, Realcan allocates directly into medical supplies, diagnostic services, and financial technology. The firm maintains dedicated operating subsidiaries for traditional drug delivery, in-vitro diagnostics, and digital health platforms, with a recent Beijing-based entity established in June 2020 to house its traditional Chinese medicine, senior care, and retail pharmacy divisions. Its balance-sheet deployment spans healthcare real assets — including the Shandong Lekang Jinyue Health Industry Park — and equity positions in financial services and logistics technology. The firm operates through a network of regionally segmented subsidiaries, each responsible for a distinct vertical: drug distribution, device logistics, lab diagnostics, and digital health. Beijing houses its retail pharmacy, traditional medicine, and real estate operations. Realcan's philanthropic arm, Realcan Big Love, sits alongside the commercial entities but with limited public disclosure about governance separation. Team size and total deployment figures remain undisclosed across public filings and media. What distinguishes Realcan from a pure distribution company is the hybrid corporate owner-operator structure. The Shenzhen listing provides permanent capital not tied to fund cycles, allowing the firm to hold both operating infrastructure and portfolio equity indefinitely. This architecture gives it the posture of a corporate investor — funding adjacent healthcare businesses from distribution cash flows — rather than a third-party logistics provider or a classic fund manager.

## Sectors

- Healthcare Services
- Pharmaceuticals & Biotech
- Logistics & Supply Chain
- FinTech
- Real Estate
- Digital Health

## Offices

- Beijing, China

## People

- Zhang Renhua — Co-founder and Chief Executive Officer
- Han Xuxiao — Co-founder and President
- Yun Feng — Chief Financial Officer

## Questions

### Who runs investment decisions at Realcan Pharmaceutical Group?

Investment and operational decisions ultimately flow through Zhang Renhua as CEO and Han Xuxiao as President, the two co-founders who have led the firm since 2004. Yun Feng serves as CFO, overseeing the capital structure that supports both distribution operations and corporate portfolio allocations. The firm has not disclosed a dedicated CIO or separate investment committee for its non-distribution activities.

### How does Realcan source its investment opportunities?

Realcan originates investments primarily through its core pharmaceutical distribution business, which provides direct visibility into the Chinese healthcare supply chain across 60,000-plus institutions. Adjacent opportunities in medical supplies, diagnostics, and fintech often emerge from existing commercial relationships with hospitals, clinics, and logistics partners. The firm does not operate an external fundraising model or solicit third-party capital.

### Where does Realcan's investment capital come from?

Realcan funds its investments through retained operating cash flows from pharmaceutical distribution and capital raised via its Shenzhen Stock Exchange listing. Unlike fund managers or family offices drawing on a single wealth pool, Realcan's balance sheet blends public-market equity, operating income, and debt capacity — a structure that imposes public-company disclosure requirements but provides permanent capital.

## Related profiles

- [Real Assets Investment Management](https://altss.com/profile/real-assets-investment-management)
- [Real Capital](https://altss.com/profile/real-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/realcan-pharmaceutical-group

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology